SCHEMBL20350896

SCHEMBL20350896

COc1cc(Br)cc2c(C)ncnc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NQO2 P16083 3/20 0.46
▸ ALDH1A1 P00352 1/20 0.44
▸ PRNP P04156 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ RXFP1 Q9HBX9 1/20 0.44
▸ EGFR P00533 3/20 0.40
▸ PDE5A O76074 2/20 0.39
▸ PIK3CA P42336 4/20 0.38
▸ HDAC1 Q13547 3/20 0.38
▸ PDE10A Q9Y233 3/20 0.37
▸ KDR P35968 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ PDE2A O00408 1/20 0.36
▸ PDE11A Q9HCR9 1/20 0.36
▸ PIK3R1 P27986 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ NCOA1 Q15788 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20351048 0.81 PIK3CA (0.38) NQO2ALDH1A1PRNPMAPTNPSR1
SCHEMBL19877629 0.81 PDE5A (0.61) NQO2ALDH1A1PRNPMAPTNPSR1
SCHEMBL19878150 0.81 ALDH1A1 (0.48) NQO2ALDH1A1PRNPMAPTNPSR1
SCHEMBL19878145 0.81 NQO2 (0.41) NQO2ALDH1A1PRNPMAPTNPSR1
SCHEMBL20351059 0.80 PIK3CA (0.39) ALDH1A1PRNPMAPTNPSR1RXFP1
SCHEMBL28449889 0.80 PIK3CA (0.39) PIK3CAHDAC1PIK3R1
SCHEMBL20813807 0.80 PDE5A (0.42) NQO2EGFRPDE5APDE10AMEN1
SCHEMBL21621172 0.79 NQO2 (0.38) NQO2ALDH1A1PRNPMAPTNPSR1
SCHEMBL28457879 0.79 PIK3CA (0.41) PIK3CAHDAC1PIK3R1
SCHEMBL24392596 0.79 PIK3CA (0.43) PDE5APIK3CAHDAC1PDE10AKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12508264-B2 Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2025-12-30 — — US disclosed
US-12508263-B2 Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2025-12-30 — — US disclosed
EP-4169917-B1 QUINAZOLINE COMPOUNDS AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER INST MATERIA MEDICA CAMS (CN) 2025-07-30 — — EP disclosed
EP-4169918-B1 QUINAZOLINE DERIVATIVES AS INHIBITORS OF PI3K FOR THE TREATMENT OF CANCER INST MATERIA MEDICA CAMS (CN) 2025-07-30 — — EP disclosed
EP-3560921-B1 QUINAZOLINE COMPOUND, PREPARATION METHOD, APPLICATION AS PI3K INHIBITOR FOR THE TREATMENT OF CANCER, AND PHARMACEUTICAL COMPOSTION THEREOF INST MATERIA MEDICA CAMS (CN) 2024-08-14 — — EP disclosed
EP-4169917-A1 QUINAZOLINE COMPOUND AND PREPARATION METHOD, APPLICATION, AND PHARMACEUTICAL COMPOSTION THEREOF Institute of Materia Medica, Chinese Academy of Medical Sciences (CN) 2023-04-26 — — EP disclosed
EP-4169918-A1 QUINAZOLINE COMPOUND AND PREPARATION METHOD, APPLICATION, AND PHARMACEUTICAL COMPOSTION THEREOF Institute of Materia Medica, Chinese Academy of Medical Sciences (CN) 2023-04-26 — — EP disclosed
US-20230110550-A1 Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMYOF MEDICAL SCIENCES (CN) 2023-04-13 — — US disclosed
US-20230113478-A1 Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMYOF MEDICAL SCIENCES (CN) 2023-04-13 — — US disclosed
US-11534443-B2 Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2022-12-27 — — US disclosed
US-11534443-B2 Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2022-12-27 — — US disclosed
CN-111646973-B Polysubstituted quinazoline derivative and preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2022-07-19 — — CN disclosed
CN-108239076-B Quinazoline compound, preparation method, application and pharmaceutical composition thereof 中国医学科学院药物研究所 2021-07-06 — — CN disclosed
US-20210128559-A1 Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2021-05-06 — — US disclosed
US-20210128559-A1 Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2021-05-06 — — US disclosed
CN-111646973-A Polysubstituted quinazoline derivative and preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2020-09-11 — — CN disclosed
EP-3560921-A1 QUINAZOLINE COMPOUND AND PREPARATION METHOD, APPLICATION, AND PHARMACEUTICAL COMPOSTION THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2019-10-30 — — EP disclosed
WO-2018121550-A1 QUINAZOLINE COMPOUND AND PREPARATION METHOD, APPLICATION, AND PHARMACEUTICAL COMPOSTION THEREOF 中国医学科学院药物研究所 2018-07-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12508263-B2 Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof PIK3CA, PIK3R5, JAK1 NQO2 1216/4885ALDH1A1 3118/4885PRNP 2877/4885
US-20230113478-A1 Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof PIK3CA, PIK3CD, PDPK1 NQO2 256/4885ALDH1A1 4244/4885PRNP 2698/4885
US-11534443-B2 Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof PIK3CA, PIK3CD, PDPK1 NQO2 256/4885ALDH1A1 4244/4885PRNP 2698/4885
US-12508264-B2 Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof PIK3CA, PIK3C2A, PIK3R5 NQO2 1060/4885ALDH1A1 3168/4885PRNP 2733/4885
US-20210128559-A1 Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof PIK3CA, PIK3CD, PDPK1 NQO2 256/4885ALDH1A1 4244/4885PRNP 2698/4885
US-20230110550-A1 Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof PIK3CA, PIK3CD, PDPK1 NQO2 256/4885ALDH1A1 4244/4885PRNP 2698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback